LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire Inc.
LAVA Therapeutics, a clinical-stage immuno-oncology company, announced that its CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference. The company is focused on developing its Gammabody platform of bispecific gamma delta T cell engagers for the treatment of solid tumors and hematologic malignancies.
Continue Reading